Enasidenib mesylate
Idhifa (enasidenib mesylate) is a small molecule pharmaceutical. Enasidenib mesylate was first approved as Idhifa on 2017-08-01. It is used to treat myeloid leukemia acute in the USA. Idhifa's patents are valid until 2034-09-16 (FDA).
| Trade Name | Idhifa |
|---|---|
| Common Name | Enasidenib mesylate |
| Indication | myeloid leukemia acute |
| Drug Class | Mutated isocitrate dehydrogenase (IDH) inhibitors |
